FIELD: pharmaceutics.
SUBSTANCE: invention relates to a method of treating primary biliary cholangitis. Method of treating primary biliary cholangitis involves oral administration of a compound, which is seladelpar or a pharmaceutically acceptable salt thereof in dose of 5 mg/day or 10 mg/day, when the dose is calculated as seladelpar.
EFFECT: method described above is effective for treating primary biliary cholangitis when using said dose of seladelpar or a pharmaceutically acceptable salt thereof, without side effects.
5 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF CHOLESTATIC ITCHING | 2018 |
|
RU2781281C2 |
| METHODS FOR INCREASING HEIGHT OF PEDIATRIC PATIENTS WITH CHOLESTATIC LIVER DISEASE | 2020 |
|
RU2822484C2 |
| METHODS OF USING AGONISTS FXR | 2017 |
|
RU2737324C2 |
| TREATMENT OF INTRAHEPATIC CHOLESTASIS AND RELATED LIVER DISEASES | 2016 |
|
RU2743405C2 |
| ORAL CHOLESTYRAMINE COMPOSITION AND APPLICATION THEREOF | 2017 |
|
RU2750937C2 |
| CHOLESTYRAMINE PELLETS, ORAL CHOLESTYRAMINE COMPOSITIONS AND THEIR USE | 2018 |
|
RU2782016C2 |
| ORAL CHOLESTYRAMINE COMPOSITION AND APPLICATION THEREOF | 2017 |
|
RU2750944C2 |
| IBAT INHIBITOR FOR TREATING HEPATIC DISORDERS | 2011 |
|
RU2591188C2 |
| FXR AGONISTS APPLICATION METHODS | 2017 |
|
RU2743075C2 |
| BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACIDS MODULATORS | 2020 |
|
RU2814570C2 |
